← Issue №11/ week of Sep 13, 2026/Endoscopy

Endoscopic management of duodenal lesions in familial adenomatous polyposis: A tertiary referral center experience.

From GI Signals issue №11: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy retrospective · n=233 · Sep 8, 2026 · Dig Liver Dis · IF 4.2

Endoscopic management of duodenal lesions in familial adenomatous polyposis: A tertiary referral center experience.

New evidencefamilial adenomatous polyposispolypectomy
Clinical takeawayFor FAP patients with duodenal lesions, endoscopic surveillance with cold snare polypectomy is safe and effective; for ampullary lesions, selective papillectomy carries low morbidity and low progression risk (selection criteria detailed in the source). This tertiary-center experience supports systematic endoscopic management as feasible in referral practice.
What it foundEndoscopic surveillance and treatment at a tertiary FAP center (233 patients, 862 EGDs, 10 years) treated 208 duodenal lesions with low-grade dysplasia in 72.4%, high-grade dysplasia in 25.9%, adenocarcinoma in 1.7%; cold snare polypectomy was most common (41.9%). Among 47 ampullary lesions, 78.7% managed with surveillance, 21.3% with papillectomy.
ContextThis observational series from a single tertiary center demonstrates safety and feasibility of endoscopic surveillance and treatment for FAP duodenal and ampullary lesions; provides supportive evidence for current surveillance strategies but does not establish comparative benefit against alternative surveillance structures.
Refinessuggested applicable standard· American College of Gastroenterology (Syngal S, Brand RE, Church JM, Kastrinos F, Lynch PM, Rubenstein JH). ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol, 2015 (Recommendations 10 and 11).

Decision at stakeWhether to actively treat duodenal lesions detected during EGD surveillance in FAP versus observation only

MUTYH-ASSOCIATED POLYPOSIS (biallelic MUTYH), colonoscopy every 1-2 years beginning at age 25-30; upper-GI surveillance by EGD/duodenoscopy from age 25-30, repeated every 0.5-4 years by Spigelman stage, plus annual thyroid ultrasound (as for classic FAP).

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

All patients meeting clinical criteria for, or carrying a pathogenic germline variant of, a hereditary GI cancer syndrome should have pre- and post-test genetic counseling, and at-risk first-degree relatives should be offered genetic testing. Syndrome-specific surveillance: LYNCH SYNDROME, colonoscopy at least every 2 years (annual colonoscopy should be considered in confirmed mutation carriers), beginning at age 20-25 years, or 2-5 years before the earliest CRC diagnosis in the family if that was before age 25; baseline EGD with gastric biopsy and test-and-treat for H. pylori at age 30-35, with ongoing upper-GI surveillance every 3-5 years where family history of gastric/duodenal cancer exists; annual endometrial biopsy and transvaginal ultrasound from age 30-35, with prophylactic hysterectomy/bilateral salpingo-oophorectomy offered after childbearing; surveillance BEYOND population-based recommendations for the urinary tract, pancreas, breast and prostate is NOT recommended unless supported by family history. CLASSIC FAP, annual sigmoidoscopy or colonoscopy beginning at puberty; colectomy indicated for documented/suspected cancer or significant symptoms (absolute), or for relative indications such as multiple adenomas >6 mm or a significant increase in adenoma number that make endoscopic control unfeasible; upper-GI surveillance by EGD/duodenoscopy from age 25-30, repeated every 0.5-4 years by Spigelman stage, plus annual thyroid ultrasound. AFAP, surveillance by colonoscopy (not sigmoidoscopy, as polyps are right-sided) with polypectomy every 1-2 years, beginning in the late teens to early 20s; upper-GI surveillance by EGD/duodenoscopy from age 25-30, repeated every 0.5-4 years by Spigelman stage, plus annual thyroid ultrasound (as for classic FAP). MUTYH-ASSOCIATED POLYPOSIS (biallelic MUTYH), colonoscopy every 1-2 years beginning at age 25-30; upper-GI surveillance by EGD/duodenoscopy from age 25-30, repeated every 0.5-4 years by Spigelman stage, plus annual thyroid ultrasound (as for classic FAP). SERRATED POLYPOSIS SYNDROME, colonoscopy every 1-3 years with attempted removal of all polyps >5 mm.

American College of Gastroenterology (Syngal S, Brand RE, Church JM, Kastrinos F, Lynch PM, Rubenstein JH). ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol, 2015 (Recommendations 10 and 11). · reviewed 2026-07-23 ↗
Scardino A … Rausa E · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №11 Every paper GI Signals surfaces gets a page like this one. All issues